As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages
that are more transmissible and resistant to currently approved antibody therapies poses a …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …

Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …

Continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
eroding antibody responses elicited by prior vaccination and infection. The SARS-CoV-2 …